A randomized, double-blind, placebo-controlled phase 1 trial of inhaled and intranasal niclosamide: A broad spectrum antiviral candidate for treatment of COVID-19
Vibeke Backer, Ulf Sjöbring, Jesper Sonne and 8 more
The Lancet Regional Health. Europe · 2021
doi:10.1016/j.lanepe.2021.100084 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.